Evidence-based, multidisciplinary approach to the development of a Crotalidae polyvalent antivenin (CroFab) protocol at a university hospital

Annals of Pharmacotherapy

Volumn 44, Issue 3, 2010, Pages 447-455

  Weant, Kyle A ^a   Johnson, Peter N ^b   Bowers, Rebecca C ^c   Armitstead, John A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antivenom; CroFab; Crotalidae; Snakebites

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CROFAB; CROTALIDAE POLYVALENT IMMUNE FAB ANTIVENIN; EQUINE DERIVED POLYVALENT ANTIVENIN; FABAV; STEROID; UNCLASSIFIED DRUG; VENOM ANTISERUM;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CLINICAL PHARMACY; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; EMERGENCY MEDICINE; ENVENOMATION; EVIDENCE BASED PRACTICE; FOLLOW UP; HEALTH CARE COST; HUMAN; HYPERSENSITIVITY REACTION; PATIENT ASSESSMENT; PATIENT CARE; PHARMACIST; PHYSICIAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESIDENT; REVIEW; SERUM SICKNESS; STANDARDIZATION; URTICARIA;

ANTIVENINS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; CROTALID VENOMS; EVIDENCE-BASED MEDICINE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; PHARMACY SERVICE, HOSPITAL; SNAKE BITES; UNITED STATES;

EID: 77749329802     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M527     Document Type: Review

References (35)

1. Parrish HM. Incidence of treated snakebites in the United States. Public Health Rep 1966;81:269-76.
2. Gold BS, Barish RA, Dart RC. North American snake envenomation: diagnosis, treatment, and management. Emerg Med Clin North Am 2004;22:423-43, ix.
3. Schmidt JM. Antivenom therapy for snakebites in children: is there evidence? Curr Opin Pediatr 2005;17:234-8.
4. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila) 2008;46:927-1057.
5. Langley RL, Morrow WE. Deaths resulting from animal attacks in the United States. Wilderness Environ Med 1997;8:8-16.
6. Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002;347:347-56.
7. Spiller HA, Bosse GM. Prospective study of morbidity associated with snakebite envenomation. J Toxicol Clin Toxicol 2003;41:125-30.
8. Jurkovich GJ, Luterman A, McCullar K, Ramenofsky ML, Curreri PW. Complications of Crotalidae antivenin therapy. J Trauma 1988;28:1032-7.
9. Package insert. CroFab (Crotalidae polyvalent immune fab (ovine). Brentwood, TN: Protherics, 2002.
10. Consroe P, Egen NB, Russell FE, et al. Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. Am J Trop Med Hyg 1995;53:507-10.
11. Lewis J. Running on empty. Drug Topics 2001;18:36.
12. Dart RC, Borron SW, Caravati EM, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med 2009;54:386-94.e1.
13. Drug topics red book annual: pharmacy's fundamental reference. 109 ed. Los Angeles: RAmEx Ars Medica, 2005.
14. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001;161:2030-6.
15. Dart RC, Seifert SA, Carroll L, et al. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning. Ann Emerg Med 1997;30:33-9.
16. Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med 1996;27:321-6.
17. Gold BS, Wingert WA. Snake venom poisoning in the United States: a review of therapeutic practice. South Med J 1994;87:579-89.
18. Offerman SR, Bush SP, Moynihan JA, Clark RF. Crotaline Fab antivenom for the treatment of children with rattlesnake envenomation. Pediatrics 2002;110:968-71.
19. Bogdan GM, Dart RC, Falbo SC, McNally J, Spaite D. Recurrent coagulopathy after antivenom treatment of crotalid snakebite. South Med J 2000;93:562-6.
20. Dart RC. Sequelae of pit viper envenomation. In: Campbell JA, Brodie ED Jr, eds. Biology of the pit vipers. Tyler, TX: Selva Publishing, 1992:395-404.
21. Lavonas EJ, Gerardo CJ, O'Malley G, et al. Initial experience with Crotalidae polyvalent immune Fab (ovine) antivenom in the treatment of copperhead snakebite. Ann Emerg Med 2004;43:200-6.
22. Hill RE, Bogdan GM, Dart RC. Time to reconstitution: purified Fab antivenom vs. unpurified IgG antivenom. Toxicon 2001;39:729-31.
23. Holstege CP, Wu J, Baer AB. Immediate hypersensitivity reaction associated with the rapid infusion of Crotalidae polyvalent immune Fab (ovine). Ann Emerg Med 2002;39:677-9.
24. Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002;39:671-6.
25. Behm MO, Kearns GL. Crotaline Fab antivenom for treatment of children with rattlesnake envenomation. Pediatrics 2003;112:1458-9; author reply, 1459.
26. Johnson PN, McGoodwin L, Banner W Jr. Utilisation of Crotalidae polyvalent immune fab (ovine) for Viperidae envenomations in children. Emerg Med J 2008;25:793-8.
27. Russell FE, Carlson RW, Wainschel J, Osborne AH. Snake venom poisoning in the United States. Experiences with 550 cases. JAMA 1975;233: 341-4.
28. Scharman EJ, Noffsinger VD. Copperhead snakebites: clinical severity of local effects. Ann Emerg Med 2001;38:55-61.
29. Van Mierop LH. Poisonous snakebite: a review. 1. Snakes and their venom. J Fla Med Assoc 1976;63:191-200.
30. Bush SP, Green SM, Moynihan JA, Hayes WK, Cardwell MD. Crotalidae polyvalent immune Fab (ovine) antivenom is efficacious for envenomations by Southern Pacific rattlesnakes (Crotalus helleri). Ann Emerg Med 2002; 40:619-24.
31. Ruha AM, Curry SC, Beuhler M, et al. Initial postmarketing experience with crotalidae polyvalent immune Fab for the treatment of rattlesnake envenomation. Ann Emerg med 2002;39:609-15.
32. Meier J, White J. Handbook of clinical toxicology of animal venoms and poisons. Boca Raton, FL: CRC Press, 1995.
33. Premawardhena AP, de Silva CE, Fonseka MM, Gunatilake SB, de Silva HJ. Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial. BMJ 1999;318:1041-3.
34. Taketomo CKH, J.H.; Kraus DM. Pediatric dosage handbook. 12th ed. Hudson, OH: Lexi-Comp Inc., 2005.
35. Geier D, Geier MR. Neurodevelopmental disorders following thimerosal-containing childhood immunizations: a follow-up analysis. Int J Toxicol 2004;23:369-76.